Subsequent in vitro experiments further confirm the impact of NME2 on various malignant characteristics of ccRCC, highlighting its potential as an important target for ccRCC treatment and a promising candidate for future drug development. Here, NME2 is linked to nonpapillary renal cell carcinoma.